UBS Downgrades StoneCo to Neutral, Announces $21 Price Target

UBS downgrades StoneCo (NASDAQ:STNE) from Buy to Neutral and announces $21 price target.

byBenzinga Newsdesk

January 4, 2022

1 minute read

UBS downgrades StoneCo (NASDAQ:STNE) from Buy to Neutral and announces $21 price target.

News

Avid Highlights New Capabilities In Co’s MediaCentral Bring Graphic Designers Into Broadcast TV And Production Workflows

By Benzinga Newsdesk

Today, 7:13 PM

TV newsrooms and production workflow teams can now bring graphic designers directly into their Avid® (NASDAQ:AVID) MediaCentral® production workflows through the MediaCentral panel, which now

AVID

Dogecoin Price Today: Is The Coin Soaring On Elon Musk Tweets?

By Madhukumar Warrier

Today, 7:13 PM

Dogecoin (CRYPTO: DOGE) traded 9% higher over 24 hours at $0.26 at press time early Monday. What’s Moving? The meme cryptocurrency has gained 9% over a seven-day trailing period.

$DOGE

Credit Suisse Maintains Outperform on Bank of Montreal, Lowers Price Target to C$157

By Benzinga Newsdesk

Today, 7:13 PM

Credit Suisse maintains Bank of Montreal (TSX:BMO) with a Outperform and lowers the price target from C$159 to C$157.

TSX:BMO

New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

By Michael Horton

Today, 7:13 PM

Statistically Significant Evidence of a Treatment Effect with OpRegen Observed in Cohort 4 Patients Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing

LCTX

UBS Downgrades StoneCo to Neutral, Announces $21 Price Target

Related Posts

Avid Highlights New Capabilities In Co’s MediaCentral Bring Graphic Designers Into Broadcast TV And Production Workflows

Dogecoin Price Today: Is The Coin Soaring On Elon Musk Tweets?

Credit Suisse Maintains Outperform on Bank of Montreal, Lowers Price Target to C$157

New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.